PROTAC Her3 Degrader-2
PROTAC Her3 Degrader-2 is a Her3 PROTAC degrader with an IC50 < 10 nM. PROTAC Her3 Degrader-2 recruits Her3 to E3 ubiquitin ligase to achieve selective degradation. PROTAC Her3 Degrader-2 can be used in the research of breast cancer, lung cancer, head and neck cancer, and prostate cancer.
(Pink: Her3 Target protein ligand; Blue: Cereblon ligand (HY-103597); Black: linker (HY-N0067)).
For research use only. We do not sell to patients.
- CAS No.: 2102694-60-8
- Formula: C44H44Cl2N8O10
- Molecular Weight:915.77
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
HER3 |
In Vitro
PROTAC Her3 Degrader-2 (Compound CY2) exhibits extremely potent target kinase binding activity in vitro, with an IC50 < 10 nM[1].
PROTAC Her3 Degrader-2 exhibits no significant Her3 protein degradation in PC9-GR4 or Ovacar 8 cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC9-GR4 and Ovacar 8 cells
-
Concentration:2 μM
-
Incubation Time:4, 8 h
-
Result:Did not exhibit significant Her3 protein degradation.
Chemical Information
-
CAS No. 2102694-60-8
-
Molecular Weight 915.77
-
Formula C44H44Cl2N8O10
-
SMILES
N#CC1=CN=C2C=C(C(OC)=CC2=C1NC3=CC(OC)=C(C=C3Cl)Cl)OCCCN4CCN(CC4)C(CCCNC(COC5=CC=CC(C(N6C7C(NC(CC7)=O)=O)=O)=C5C6=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PROTAC Her3 Degrader-2 Related Classifications
HY-103630 Related Classifications
Powered by Bioz